vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $13.8M, roughly 1.7× CB Financial Services, Inc.). On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 19.9%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-69.4M). Over the past eight quarters, CB Financial Services, Inc.'s revenue compounded faster (1.2% CAGR vs -10.8%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
CBFV vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $23.0M |
| Net Profit | — | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 38.1% | -428.9% |
| Net Margin | — | -416.2% |
| Revenue YoY | 19.9% | 78.8% |
| Net Profit YoY | — | 25.7% |
| EPS (diluted) | $0.90 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $23.0M | ||
| Q3 25 | $2.4M | $13.8M | ||
| Q2 25 | $13.5M | $14.2M | ||
| Q1 25 | $12.1M | $16.6M | ||
| Q4 24 | $13.2M | $12.9M | ||
| Q3 24 | $12.7M | $9.1M | ||
| Q2 24 | $12.2M | $7.0M | ||
| Q1 24 | $13.5M | $28.9M |
| Q4 25 | — | $-95.8M | ||
| Q3 25 | $-5.7M | $-101.3M | ||
| Q2 25 | $3.9M | $-101.3M | ||
| Q1 25 | $1.9M | $-114.3M | ||
| Q4 24 | — | $-128.9M | ||
| Q3 24 | $3.2M | $-135.7M | ||
| Q2 24 | $2.6M | $-147.0M | ||
| Q1 24 | $4.2M | $-107.4M |
| Q4 25 | 38.1% | -428.9% | ||
| Q3 25 | -289.8% | -808.9% | ||
| Q2 25 | 35.0% | -772.2% | ||
| Q1 25 | 19.3% | -726.6% | ||
| Q4 24 | 23.1% | -1059.9% | ||
| Q3 24 | 31.2% | -1589.0% | ||
| Q2 24 | 26.4% | -1998.6% | ||
| Q1 24 | 37.9% | -394.0% |
| Q4 25 | — | -416.2% | ||
| Q3 25 | -235.2% | -735.2% | ||
| Q2 25 | 29.3% | -710.8% | ||
| Q1 25 | 15.8% | -687.6% | ||
| Q4 24 | — | -1001.2% | ||
| Q3 24 | 25.3% | -1489.5% | ||
| Q2 24 | 21.8% | -2112.6% | ||
| Q1 24 | 31.1% | -371.3% |
| Q4 25 | $0.90 | $-0.81 | ||
| Q3 25 | $-1.07 | $-0.92 | ||
| Q2 25 | $0.74 | $-0.98 | ||
| Q1 25 | $0.35 | $-1.10 | ||
| Q4 24 | $0.45 | $-1.27 | ||
| Q3 24 | $0.60 | $-1.34 | ||
| Q2 24 | $0.51 | $-1.52 | ||
| Q1 24 | $0.82 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $157.5M | $671.4M |
| Total Assets | $1.5B | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $449.9M | ||
| Q3 25 | $55.9M | $511.0M | ||
| Q2 25 | $64.5M | $459.7M | ||
| Q1 25 | $61.3M | $503.7M | ||
| Q4 24 | $49.6M | $601.5M | ||
| Q3 24 | $147.3M | $658.1M | ||
| Q2 24 | $142.6M | $691.1M | ||
| Q1 24 | $73.7M | $791.3M |
| Q4 25 | $157.5M | $671.4M | ||
| Q3 25 | $152.5M | $748.4M | ||
| Q2 25 | $148.4M | $715.3M | ||
| Q1 25 | $148.3M | $779.9M | ||
| Q4 24 | $147.4M | $872.0M | ||
| Q3 24 | $149.1M | $962.6M | ||
| Q2 24 | $142.9M | $971.1M | ||
| Q1 24 | $141.6M | $1.0B |
| Q4 25 | $1.5B | $842.1M | ||
| Q3 25 | $1.5B | $925.3M | ||
| Q2 25 | $1.5B | $898.9M | ||
| Q1 25 | $1.5B | $986.2M | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.5B | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-69.3M |
| Free Cash FlowOCF − Capex | $17.2M | $-69.4M |
| FCF MarginFCF / Revenue | 124.1% | -301.6% |
| Capex IntensityCapex / Revenue | 4.7% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $-69.3M | ||
| Q3 25 | $4.6M | $-76.9M | ||
| Q2 25 | $4.1M | $-99.6M | ||
| Q1 25 | $4.0M | $-148.9M | ||
| Q4 24 | $6.8M | $-85.2M | ||
| Q3 24 | $3.1M | $-84.8M | ||
| Q2 24 | $-1.2M | $-58.2M | ||
| Q1 24 | $3.3M | $-120.7M |
| Q4 25 | $17.2M | $-69.4M | ||
| Q3 25 | $4.5M | $-76.9M | ||
| Q2 25 | $3.9M | $-99.9M | ||
| Q1 25 | $3.9M | $-149.7M | ||
| Q4 24 | $3.4M | $-86.2M | ||
| Q3 24 | $2.2M | $-86.1M | ||
| Q2 24 | $-2.4M | $-59.2M | ||
| Q1 24 | $2.3M | $-123.2M |
| Q4 25 | 124.1% | -301.6% | ||
| Q3 25 | 186.5% | -558.2% | ||
| Q2 25 | 28.8% | -701.0% | ||
| Q1 25 | 32.5% | -900.1% | ||
| Q4 24 | 26.0% | -669.4% | ||
| Q3 24 | 17.4% | -945.2% | ||
| Q2 24 | -19.6% | -850.9% | ||
| Q1 24 | 17.0% | -425.7% |
| Q4 25 | 4.7% | 0.5% | ||
| Q3 25 | 4.3% | 0.2% | ||
| Q2 25 | 1.9% | 1.7% | ||
| Q1 25 | 0.8% | 4.4% | ||
| Q4 24 | 25.1% | 7.6% | ||
| Q3 24 | 6.7% | 14.0% | ||
| Q2 24 | 10.0% | 14.5% | ||
| Q1 24 | 7.2% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
